Contact
Please use this form to send email to PR contact of this press release:
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B
TO:
Please use this form to send email to PR contact of this press release:
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B
TO: